2019 Q2 Form 10-Q Financial Statement
#000156459020038994 Filed on August 10, 2020
Income Statement
| Concept | 2019 Q2 |
|---|---|
| Revenue | $880.3K |
| YoY Change | 39.21% |
| Cost Of Revenue | $125.0K |
| YoY Change | -37.64% |
| Gross Profit | $755.3K |
| YoY Change | 74.88% |
| Gross Profit Margin | 85.8% |
| Selling, General & Admin | $2.800M |
| YoY Change | 6.59% |
| % of Gross Profit | 370.71% |
| Research & Development | $535.9K |
| YoY Change | 10.05% |
| % of Gross Profit | 70.95% |
| Depreciation & Amortization | $23.45K |
| YoY Change | 17.25% |
| % of Gross Profit | 3.1% |
| Operating Expenses | $3.336M |
| YoY Change | 7.13% |
| Operating Profit | -$2.581M |
| YoY Change | -3.78% |
| Interest Expense | $141.0K |
| YoY Change | 182.93% |
| % of Operating Profit | |
| Other Income/Expense, Net | |
| YoY Change | |
| Pretax Income | -$2.565M |
| YoY Change | -2.46% |
| Income Tax | |
| % Of Pretax Income | |
| Net Earnings | -$2.565M |
| YoY Change | -2.44% |
| Net Earnings / Revenue | -291.4% |
| Basic Earnings Per Share | |
| Diluted Earnings Per Share | -$4.500M |
| COMMON SHARES | |
| Basic Shares Outstanding | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2019 Q2 |
|---|---|
| SHORT-TERM ASSETS | |
| Cash & Short-Term Investments | $6.669M |
| YoY Change | -42.9% |
| Cash & Equivalents | $6.669M |
| Short-Term Investments | |
| Other Short-Term Assets | $817.5K |
| YoY Change | 77.71% |
| Inventory | $349.2K |
| Prepaid Expenses | |
| Receivables | $331.0K |
| Other Receivables | $0.00 |
| Total Short-Term Assets | $8.167M |
| YoY Change | -36.09% |
| LONG-TERM ASSETS | |
| Property, Plant & Equipment | $192.6K |
| YoY Change | 17.53% |
| Goodwill | |
| YoY Change | |
| Intangibles | |
| YoY Change | |
| Long-Term Investments | |
| YoY Change | |
| Other Assets | $183.4K |
| YoY Change | 52.83% |
| Total Long-Term Assets | $376.0K |
| YoY Change | 30.6% |
| TOTAL ASSETS | |
| Total Short-Term Assets | $8.167M |
| Total Long-Term Assets | $376.0K |
| Total Assets | $8.543M |
| YoY Change | -34.63% |
| SHORT-TERM LIABILITIES | |
| YoY Change | |
| Accounts Payable | $429.5K |
| YoY Change | 26.31% |
| Accrued Expenses | $947.4K |
| YoY Change | -10.62% |
| Deferred Revenue | $40.00 |
| YoY Change | |
| Short-Term Debt | $0.00 |
| YoY Change | |
| Long-Term Debt Due | |
| YoY Change | |
| Total Short-Term Liabilities | $1.436M |
| YoY Change | -8.56% |
| LONG-TERM LIABILITIES | |
| Long-Term Debt | $0.00 |
| YoY Change | |
| Other Long-Term Liabilities | $0.00 |
| YoY Change | -100.0% |
| Total Long-Term Liabilities | $0.00 |
| YoY Change | -100.0% |
| TOTAL LIABILITIES | |
| Total Short-Term Liabilities | $1.436M |
| Total Long-Term Liabilities | $0.00 |
| Total Liabilities | $1.436M |
| YoY Change | -11.13% |
| SHAREHOLDERS EQUITY | |
| Retained Earnings | -$50.58M |
| YoY Change | 26.61% |
| Common Stock | $57.69M |
| YoY Change | 4648521.51% |
| Preferred Stock | |
| YoY Change | |
| Treasury Stock (at cost) | $6.464K |
| YoY Change | 0.0% |
| Treasury Stock Shares | |
| Shareholders Equity | $7.061M |
| YoY Change | |
| Total Liabilities & Shareholders Equity | $8.543M |
| YoY Change | -34.63% |
Cashflow Statement
| Concept | 2019 Q2 |
|---|---|
| OPERATING ACTIVITIES | |
| Net Income | -$2.565M |
| YoY Change | -2.44% |
| Depreciation, Depletion And Amortization | $23.45K |
| YoY Change | 17.25% |
| Cash From Operating Activities | -$2.288M |
| YoY Change | -2.24% |
| INVESTING ACTIVITIES | |
| Capital Expenditures | -$29.50K |
| YoY Change | 47.5% |
| Acquisitions | |
| YoY Change | |
| Other Investing Activities | |
| YoY Change | |
| Cash From Investing Activities | -$29.50K |
| YoY Change | 47.5% |
| FINANCING ACTIVITIES | |
| Cash Dividend Paid | |
| YoY Change | |
| Common Stock Issuance & Retirement, Net | |
| YoY Change | |
| Debt Paid & Issued, Net | |
| YoY Change | |
| Cash From Financing Activities | -247.7K |
| YoY Change | 395.3% |
| NET CHANGE | |
| Cash From Operating Activities | -2.288M |
| Cash From Investing Activities | -29.50K |
| Cash From Financing Activities | -247.7K |
| Net Change In Cash | -2.565M |
| YoY Change | 6.42% |
| FREE CASH FLOW | |
| Cash From Operating Activities | -$2.288M |
| Capital Expenditures | -$29.50K |
| Free Cash Flow | -$2.258M |
| YoY Change | -2.67% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2019Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
1495 | |
| CY2019Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-56125982 | |
| CY2020Q2 | us-gaap |
Other Long Term Debt
OtherLongTermDebt
|
77892 | |
| CY2019Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
888961 | |
| CY2019Q4 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
6464 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1824708 | |
| us-gaap |
Gross Profit
GrossProfit
|
1043520 | ||
| CY2019Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2019Q4 | us-gaap |
Liabilities
Liabilities
|
4773985 | |
| CY2019Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
6598693 | |
| CY2019Q4 | us-gaap |
Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
|
676703 | |
| CY2019Q4 | us-gaap |
Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
|
36169 | |
| CY2019Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
574524 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
574497 | |
| CY2019Q4 | us-gaap |
Treasury Stock Common Shares
TreasuryStockCommonShares
|
27 | |
| us-gaap |
Cost Of Revenue
CostOfRevenue
|
666895 | ||
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
873921 | ||
| us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
5558739 | ||
| us-gaap |
Operating Expenses
OperatingExpenses
|
6432660 | ||
| us-gaap |
Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
|
141420 | ||
| us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-84333 | ||
| us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
206668 | ||
| us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-507281 | ||
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
225753 | ||
| CY2020Q1 | myo |
Common Stock Issued For Warrants Exercised
CommonStockIssuedForWarrantsExercised
|
161250 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
123209 | |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-5163387 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-11.15 | ||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
1698 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-5163387 | ||
| us-gaap |
Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
|
-797637 | ||
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-5961024 | ||
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
534452 | ||
| CY2020Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
13475535 | |
| CY2020Q1 | myo |
Proceeds From Issuance Of Prefunded Warrants In Conjunction With Public Offering
ProceedsFromIssuanceOfPrefundedWarrantsInConjunctionWithPublicOffering
|
48 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3801993 | |
| CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
11782757 | |
| CY2020Q2 | myo |
Proceeds From Issuances Under At Market Sales Facility Value
ProceedsFromIssuancesUnderAtMarketSalesFacilityValue
|
542586 | |
| CY2020Q2 | myo |
Issuances Of Common Stock Value Repay Debt
IssuancesOfCommonStockValueRepayDebt
|
910420 | |
| CY2020Q2 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
|
-1855 | |
| CY2020Q2 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
106281 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
6425885 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
5603829 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
|
-72115 | |
| CY2019Q1 | us-gaap |
Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
|
1 | |
| CY2019Q1 | myo |
Warrants Issued As Offering Costs And Recorded As Derivative Liability
WarrantsIssuedAsOfferingCostsAndRecordedAsDerivativeLiability
|
-196236 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
396325 | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2598060 | |
| CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
9436182 | |
| CY2019Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
15 | |
| CY2019Q2 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
|
-6356 | |
| CY2019Q2 | us-gaap |
Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
|
-72 | |
| CY2019Q2 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
197028 | |
| CY2019Q1 | myo |
Offering Cost From Sale Of Shares
OfferingCostFromSaleOfShares
|
710572 | |
| CY2020Q1 | myo |
Offering Cost From Sale Of Shares
OfferingCostFromSaleOfShares
|
1499370 | |
| CY2019 | myo |
Offering Cost From Sale Of Shares
OfferingCostFromSaleOfShares
|
29277 | |
| CY2019Q1 | us-gaap |
Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
|
1515 | |
| CY2019Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
7061470 | |
| us-gaap |
Depreciation
Depreciation
|
53021 | ||
| CY2019Q2 | us-gaap |
Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
|
234 | |
| CY2020Q2 | us-gaap |
Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
|
489 | |
| us-gaap |
Profit Loss
ProfitLoss
|
-7088927 | ||
| us-gaap |
Profit Loss
ProfitLoss
|
-5163387 | ||
| us-gaap |
Depreciation
Depreciation
|
45076 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
229490 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
593353 | ||
| us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
45839 | ||
| us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
143026 | ||
| myo |
Fair Value Of Warrants And Derivative Liabilities
FairValueOfWarrantsAndDerivativeLiabilities
|
121818 | ||
| myo |
Fair Value Of Warrants And Derivative Liabilities
FairValueOfWarrantsAndDerivativeLiabilities
|
141420 | ||
| us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
-177 | ||
| us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
-2481 | ||
| us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
2981 | ||
| us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-12606 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-67931 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-51245 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
243336 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
195397 | ||
| myo |
Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
|
100127 | ||
| myo |
Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
|
161014 | ||
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-57987 | ||
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-23574 | ||
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
51292 | ||
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-473118 | ||
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
5787 | ||
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-1420 | ||
| us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
77892 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-6110798 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-5407421 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
7878 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
34903 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-7878 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-34903 | ||
| us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
1703552 | ||
| us-gaap |
Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
|
255533 | ||
| myo |
Proceeds From Payments Related To Tax Withholding For Share Based Compensation
ProceedsFromPaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
-1855 | ||
| myo |
Proceeds From Payments Related To Tax Withholding For Share Based Compensation
ProceedsFromPaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
-78542 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
3 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
15 | ||
| us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
161298 | ||
| myo |
Proceeds From Issuance Under At Market Sales Facility
ProceedsFromIssuanceUnderAtMarketSalesFacility
|
674562 | ||
| us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
13504812 | ||
| us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
5648928 | ||
| myo |
Proceeds From Payment Of Grants
ProceedsFromPaymentOfGrants
|
6928 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
12386663 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
5570401 | ||
| us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
-23 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
6267964 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
128077 | ||
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
4540455 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
6615794 | |
| CY2020Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
10808419 | |
| CY2019Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
6743871 | |
| myo |
Inventory Capitalized As Sales Demo Equipment
InventoryCapitalizedAsSalesDemoEquipment
|
2743 | ||
| myo |
Inventory Capitalized As Sales Demo Equipment
InventoryCapitalizedAsSalesDemoEquipment
|
17715 | ||
| us-gaap |
Property Plant And Equipment Transfers And Changes
PropertyPlantAndEquipmentTransfersAndChanges
|
2514 | ||
| myo |
Issuance Of Warrants Recorded As Derivative Liability
IssuanceOfWarrantsRecordedAsDerivativeLiability
|
196236 | ||
| myo |
Deferred Issuance Costs To Additional Paid In Capital Paid In Prior Period
DeferredIssuanceCostsToAdditionalPaidInCapitalPaidInPriorPeriod
|
161253 | ||
| us-gaap |
Stock Issued1
StockIssued1
|
910420 | ||
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 1 — Description of Business</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Myomo Inc. (“Myomo” or the Company”) is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro ® myoelectric upper limb orthosis product is registered with the U.S. Food and Drug Administration as a Class II medical device. The Company sells its products directly to patients, to orthotics and prosthetics (O&P) providers, the Veterans Health Administration, rehabilitation hospitals, and through distributors.<font style="font-family:Calibri;"> </font>When we provide devices directly to patients and bill their insurance companies directly, we may evaluate, cast and fit the MyoPro devices using our own clinical staff or utilize the clinical consulting services of O&P professionals for which they are paid a fee. The Company was incorporated in the State of Delaware on September 1, 2004 and is headquartered in Cambridge, Massachusetts.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Amended and Restated Certificate of Incorporation and Reverse Stock Split</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 30, 2020, the Company filed with the State of Delaware an amendment to its Eighth Amended and Restated Certificate of Incorporation for a one-for-thirty reverse stock split of the Company’s common stock. All share and per share information has been restated retroactively, giving effect to the reverse stock split for all periods presented. There was no change to reported net loss in any period presented.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Liquidity<font style="font-style:normal;"> </font>and Impact of COVID-19</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incurred net losses of approximately $7.1 million and $5.2 million during the six months ended June 30, 2020 and 2019, respectively, and has an accumulated deficit of approximately $63.2 million and $56.1 million at June 30, 2020 and December 31, 2019, respectively. Cash used in operating activities was approximately $6.1 million and $5.4 million for the six months ended June 30, 2020 and 2019, respectively. The Company has historically funded its operations through financing activities, including raising equity and debt capital.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The outbreak of the novel coronavirus, SARS-CoV-2, which causes coronavirus disease 2019 (“COVID-19”), has evolved into a global pandemic. COVID-19 has spread to many regions of the world, including the United States and Europe. In response to the pandemic, the Company has implemented a work from home policy, with substantially all employees continuing their work outside of the Company’s offices. While the Company was able to continue with certain parts of its business, such as lead generation and patient evaluations, public health and societal restrictions in place during the second quarter of 2020 adversely impacted other aspects of the Company’s business. For example, the Company provides a custom-fabricated device to each patient and in-person contact is required as part of the fabrication and delivery process. As a result of COVID-19-related public health restrictions on travel and personal interaction, fabrication and delivery processes were suspended during the majority of the second quarter of 2020. As a result of these restrictions, the Company’s ability to deliver its products to patients and to generate revenues was negatively affected. Similarly, the impairment in the ability for patient consultation and fittings is expected to delay for several months the launch of MyoPal, its new product for pediatric patients. While the Company has resumed in-person interactions with, and deliveries to, patients, incidences of the virus are increasing in certain parts of the United States and the world. Public health restrictions may be reinstated in these and other areas in the future. In addition, entities such as the Veteran’s Administration (“VA”) continue to have restrictions on seeing patients other than those affected by COVID-19. While insurance reimbursement practices of government and third-party payers are so far largely unaffected by the pandemic, the Company can provide no assurance that will continue in the future. Similarly, it is unclear to what extent an extended period of significant unemployment will reduce the number of prospective candidates due to loss of health insurance. The Company has sufficient inventory of subassemblies available, and its contract manufacturing partners have either continued to operate or have resumed operations. While the Company has experienced some minor extensions of lead times in its supply chain, the Company believes it has sufficient inventories of all critical components. </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2020, the Company eliminated certain positions, furloughed other employees and reduced certain expenses in response to the adverse impact of the pandemic on its business. As of the date of this Quarterly Report on Form 10-Q, almost all furloughed employees have returned to work. The Company has a growing backlog of patients authorized by insurance companies to receive a MyoPro. In addition, the Company utilized its At-Market Sales Facility (“ATM facility”) during the second quarter to raise additional capital (see Note 6). The remaining capacity under the Company’s shelf registration statement on Form S-3 totals approximately $13.1 million. However, due to the Company’s public float, the amount of securities the Company may sell from time to time under such registration statement is subject to the limitations imposed by General Instruction I.B.6 of Form S-3.<font style="color:#000000;"> </font>As a result, the Company believes that its existing cash is sufficient to sustain its operations for a period of twelve months from the filing date of this Quarterly Report on Form 10-Q. However, if public health restrictions on travel and patient interaction are broadly reinstated, it is likely that the Company will need to raise additional capital to sustain its operations beyond the first half of 2021.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s operating plans are primarily focused on growing the number of MyoPro units provided to patients, increasing the proportion of patients carrying commercial health insurance with payers that have historically reimbursed for the Company’s products, executing on its plans to complete development of its pediatric product when public health conditions allow and continued work with the Centers for Medicare and Medicaid Services, or CMS, and their billing contractors regarding reimbursement of its products. In addition, the Company believes that it has access to capital resources through possible public or private equity offerings, including usage of its ATM facility, exercises of outstanding warrants, additional debt financings, or other means. Additional debt financing requires the consent of Chicago Venture Partners (“CVP”), and may require the Company to pledge other assets not currently pledged and enter into covenants that could restrict certain business activities or its ability to incur further indebtedness; and may contain other terms that are not favorable to the Company or its stockholders. </p> | ||
| us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain prior year amounts in research and development and sales and marketing expenses have been reclassified to cost of goods sold to conform with the current year presentation. Certain current liabilities have been reclassified as Accounts payable and accrued expenses to conform with the current year presentation.</p> | ||
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from these estimates. The Company’s significant estimates include the allowance for doubtful accounts, deferred tax valuation allowances, warranty obligations and derivative liabilities.</p> | ||
| CY2020Q2 | myo |
Remaining Capital Amount Under Shelf Registration
RemainingCapitalAmountUnderShelfRegistration
|
13100000 | |
| CY2019Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-3395697 | |
| CY2019Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-6.82 | |
| us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-5961024 | ||
| us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-8749142 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-15.99 | ||
| CY2019 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-11510646 | |
| CY2019 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-20.79 | |
| CY2020Q2 | us-gaap |
Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
|
111027 | |
| CY2019Q4 | us-gaap |
Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
|
81981 | |
| CY2020Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
150420 | |
| CY2019Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
174021 | |
| CY2020Q2 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
1689031 | |
| CY2019Q4 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
1738490 | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2540599 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
220971 | ||
| CY2020Q2 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
72584 | |
| CY2019Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
46854 | |
| CY2020Q2 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
38000 | |
| CY2020Q2 | myo |
Inventory Rental Units
InventoryRentalUnits
|
58237 | |
| CY2019Q4 | myo |
Inventory Rental Units
InventoryRentalUnits
|
23418 | |
| CY2020Q2 | us-gaap |
Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
|
517405 | |
| CY2019Q4 | us-gaap |
Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
|
372996 | |
| CY2020Q2 | us-gaap |
Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
|
686226 | |
| CY2019Q4 | us-gaap |
Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
|
443268 | |
| CY2020Q2 | myo |
Inventory Reserve For Rental Units
InventoryReserveForRentalUnits
|
-7320 | |
| CY2019Q4 | myo |
Inventory Reserve For Rental Units
InventoryReserveForRentalUnits
|
-3735 | |
| CY2020Q2 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
10214935 | |
| CY2019Q4 | us-gaap |
Derivative Liabilities
DerivativeLiabilities
|
378239 | |
| CY2020Q1 | myo |
Payment Against Derivative Liability
PaymentAgainstDerivativeLiability
|
-255533 | |
| CY2020Q1 | us-gaap |
Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
|
-82101 | |
| CY2020Q1 | us-gaap |
Derivative Liabilities
DerivativeLiabilities
|
40605 | |
| CY2020Q2 | us-gaap |
Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
|
-39717 | |
| CY2020Q2 | us-gaap |
Derivative Liabilities
DerivativeLiabilities
|
888 | |
| CY2018Q4 | us-gaap |
Derivative Liabilities
DerivativeLiabilities
|
3661 | |
| CY2019Q1 | us-gaap |
Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
|
196236 | |
| CY2020Q2 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | |
| CY2019Q1 | us-gaap |
Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
|
-41971 | |
| us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
0 | ||
| CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
0 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
19.20 | ||
| CY2020Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
106281 | |
| CY2019Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y7M6D | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y5M15D | ||
| CY2019Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
15.90 | |
| CY2019Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
3416 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
5883 | ||
| CY2019Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
|
0.6324 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
|
0.6253 | ||
| CY2019Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0193 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0217 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
593353 | ||
| CY2020Q2 | us-gaap |
Revenue From Related Parties
RevenueFromRelatedParties
|
40900 | |
| us-gaap |
Revenue From Related Parties
RevenueFromRelatedParties
|
40900 | ||
| CY2019Q2 | us-gaap |
Revenue From Related Parties
RevenueFromRelatedParties
|
0 | |
| us-gaap |
Revenue From Related Parties
RevenueFromRelatedParties
|
26000 | ||
| CY2020Q2 | us-gaap |
Accounts Receivable Related Parties
AccountsReceivableRelatedParties
|
25900 | |
| CY2019Q4 | us-gaap |
Accounts Receivable Related Parties
AccountsReceivableRelatedParties
|
25900 | |
| CY2020Q2 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
84600 | |
| us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
188100 | ||
| CY2019Q2 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
125000 | |
| us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
235000 | ||
| CY2020Q2 | us-gaap |
Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
|
43800 | |
| CY2019Q4 | us-gaap |
Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
|
47800 |
